137
Views
25
CrossRef citations to date
0
Altmetric
Original Article

Disposition of Mesalazine from Mesalazine-Delivering Drugs in Patients with Inflammatory Bowel Disease, with and without Diarrhoea

, &
Pages 863-868 | Received 23 Jan 1992, Accepted 11 May 1992, Published online: 08 Jul 2009

References

  • Sandberg-Gertzén H, Ryde H, Järnerot G. Absorption and excretion of a single 1 g dose of azodisal sodium in subjects with ileostomy. Scand J Gastroenterol 1983; 18: 107–11
  • Rasmussen SN, Bondesen S, Hvidberg EF, et al. 5-Amino-salicylic acid in a slow-release preparation: bioavailability, plasma level, and excretion in humans. Gastroenterology 1982; 83: 1062–70
  • Dew MJ, Hughes PJ, Lee MG, Evan BK, Rhodes J. An oral preparation to release drugs in the human colon. Br J Clin Pharmacol 1982; 14: 405–8
  • Van Hogezand RA, Van Hees PAM, Zwanenburg B, Van Rossum JM, Van Tongeren JUM. Disposition of disodium azo-disalicylate in healthy subjects. Gastroenterology 1985; 88: 717–22
  • Klotz U, Maicr KE, Fischer C, Bauer KH. A new slow-release form of 5-aminosalicylic acid for the oral treatment of inflammatory bowel disease. Drug Res 1985; 35: 636–9
  • Rijk MCM, Van Schaik A, Van Tongeren JHM. Disposition of 5-aminosalicylic acid by 5-aminosalicylic acid-delivering compounds. Scand J Gastroenterol 1988; 23: 107–12
  • Van Hees PAM, Tuinte JHM, van Rossum JM, van Tongeren JIIM. Influence of intestinal transit time on azo-reduction of salicylazosulphapyridine (Salazopyrin). Gut 1979; 20: 300–4
  • Christensen LA, Slot O, Sanchez G, et al. Release of 5-aminosalicylic acid from Pcntasa® during normal and accelerated transit time. Br .1 Clin Pharmacol 1987; 23: 365–9
  • Rijk MCM, van Hogezand RA, van Schaik A, Van Tongeren JHM. Disposition of 5-aminosalicylic acid from 5-aminosalicylic acid-delivering drugs during accelerated intestinal transit in healthy volunteers. Scand J Gastroenterol 1989; 24: 1179–85
  • Klotz U, Maicr KE, Bauer KH. A new slow-release form of 5-aminosalicylic acid for the oral treatment of inflammatory bowel disease. Drug Res 1985; 3: 636–9
  • Lauritsen K, Staerk Laursen L, Bukhave K, Rask-Madsen J. Longterm olsalazine treatment: pharmacokinetics, tolerance and effects on local eicosanoid formation in ulcerative colitis and Crohn's colitis. Gut 1988; 29: 974–82
  • Dull BJ, Salata K, Goldman P. Role of intestinal flora in the acetylation of sulphasalazine metabolites. Biochem Pharmacol 1987; 36: 3772–4
  • Allgayer H, Ahnfelt NO, Kruis W, et al. Colonic N-acethylation of 5-aminosalicylic acid in inflammatory bowel disease. Gastroenterology 1989; 97: 38–41
  • Nielsen OH, Bondesen S. Kinetics of 5-aminosalicylic acid after jejunal instillation in man. Br J Clin Pharmacol 1983; 16: 738–40
  • Myers B, Evans DNW, Rhodes J, et al. Metabolism and urinary excretion of 5-aminosalicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. Gut 1987; 28: 196–200
  • Truelovc SC, Witts LJ. Cortisone in ulcerative colitis. Final report on a therapeutical trial. Br Med J 1955; 2: 1041–8
  • van Hees PAM, van Elteren Ph, van Lier HJJ, van Tongeren JHM. An index of inflammatory activity in patients with Crohn's disease. Gut 1980; 21: 279–86
  • van Hogezand RA, van Schaik A, van Hees PAM, Van Tongeren JHM. Stability of disodium azodisalicylate and metabolites in urine and faeces stored at different temperatures. 5-Aminosalicylie acid compounds. Pharmacokinetic and clinical aspects, RA van Hogezand. thesis, University of Nijmegen, Nijmegen 1986
  • Cummings JII, Wiggins HS. Transit through the gut measured by analysis of a single stool. Gut 1976; 17: 219–23
  • Hinton JM, Lennard-Jones JE, Young AC. A new method for studying gut transit times using radioopaque markers. Gut 1969; 10: 842–7
  • Staerk Laursen L, Stokholm M, Bukhave K, Rask-Madsen J, Lauritsen K. Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations: comparison of intraluminal colonic concentrations, serum values, and urinary excretion. Gut 1990; 31: 1271–6
  • Willoughby CP, Piris J, Truelove SC. The effect of topical N-acetyl-5-aminosalicylic acid in ulcerative colitis. Scand J Gastroenterol 1980; 15: 715–9
  • Binder V, Halskov S, Hvidberg E, et al. A controlled study of 5-acctyl-aminosalicylic acid (5-AC-ASA) as enema in ulcerative colitis [abstract]. Scand J Gastroenterol 1981; 16: 1122
  • van Hogezand RA, van Hees PAM, van Gorp JPWM, et al. Effect of 5-aminosalicylic acid (mesalazine) and acetyl-5-aminosalicylic acid (ac-mesalazine) suppositories in patients with idiopathic proctitis. A double blind study. Aliment Pharmacol Ther 1988; 2: 33–40
  • Mulder CJJ, Tytgat NJ, Weterman IT, et al. Double-blind comparison of slow-release 5-aminosalicylic acid and sulphasalazine in remission maintenance in ulcerative colitis. Gastroenterology 1988; 95: 1449–53

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.